Noramco Seeks Federal Approval to Import Marijuana and Methadone
Published Date: 11/5/2026
Notice
Summary
Noramco wants to become an official importer of some controlled substances like marijuana and methadone. People who make or apply to handle these drugs can share their thoughts or ask for a hearing by December 7, 2026. This move could affect companies dealing with these substances and involves a formal review process with no immediate cost changes announced.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Noramco applied to import listed controlled drugs
On September 21, 2026, Noramco applied to be registered as an importer for the listed basic classes of controlled substances, including Gamma Hydroxybutyric Acid (code 2010, Schedule I), Marihuana (7360, Schedule I), Tetrahydrocannabinols (7370, Schedule I), Methadone-Intermediate (9254, Schedule II), Opium and related codes (9600–9650 range, Schedule II), Noroxymorphone (9668, Schedule II), Poppy Straw Concentrate (9670, Schedule II), and Tapentadol (9780, Schedule II).
Import planned of poppy straw concentrate
Noramco plans to import Poppy Straw Concentrate (drug code 9670, Schedule II) to bulk manufacture other controlled substances and distribute them to its customers.
Import planned of Tapentadol intermediate
Noramco plans to import an intermediate form of Tapentadol (drug code 9780, Schedule II) to bulk manufacture Tapentadol for distribution to its customers.
Registration excludes finished dosage imports
The notice explicitly states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22555, Importer of Controlled Substances Application: Diamond Animal Health, Inc.
Diamond Animal Health, Inc. wants to become an official importer of a controlled drug called Pentobarbital, which is used in animal health. People who make or use these drugs can share their thoughts or ask for a hearing by December 7, 2026. This move could affect businesses handling these substances and involves careful government review but no direct costs mentioned yet.
2026-22289, Bulk Manufacturer of Controlled Substances Application: AJNA Biosciences
AJNA Biosciences wants to become a big-time producer of marijuana and related substances for research and clinical trials. This means they’ll grow and handle these controlled substances under strict rules, helping science move forward. If you have thoughts or objections, you’ve got until January 4, 2027, to speak up!
Previous / Next Documents
Previous: 2026-22552, Notice of Open Meeting for the 2026-2027 EXIM Advisory Committee
The Export-Import Bank is holding an open virtual meeting on November 19, 2026, to talk about new ways to help U.S. businesses get financing for their goods and services. Anyone interested can join online by registering and even share their thoughts during or after the meeting. This is a great chance for businesses and the public to influence how U.S. exports get supported in the coming year.
Next: 2026-22554, Tribal Intergovernmental Advisory Committee Request for Member Nominations; Extension of Comment Period
HUD is giving tribes and interested folks 30 more days to nominate members for the Tribal Intergovernmental Advisory Committee. If you want to help shape housing programs for Native communities, now’s your chance! Just submit your nominations online by December 4, 2026—no mail or fax allowed.